摘要
贝曲沙班是新型的口服Ⅹa因子抑制剂,由美国食品和药物管理局于2017年6月23日批准上市,用于因急性内科疾病住院患者预防静脉血栓栓塞及并发症的发生,是目前经肾脏排泄最少的抗凝药,可用于严重肾功能不全的患者。本文对贝曲沙班的药效学、药动学、临床试验及安全性等作一综述。
Betrixaban is a novel drug of factor Ⅹa inhibitor approved by U.S. Food and Drug Administration for the prophylaxis of venous thromboembolism and complications in adult patients hospitalized for an acute medical illness on June 23, 2017. Betrixaban has the lowest renal excretion among the present oral anticoagulants, so it can be prescribed to patients with severe renal insufficiency. The pharmacodynamics,pharmacokinetics, clinical trials and the adverse reactions about betrixaban were interviewed in this paper.
作者
巩萍
GONG Ping(Department of Pharmacy,the People Is Hospital of Linqu,Linqu SHANDONG 262600,Chin)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2018年第7期388-391,共4页
Chinese Journal of New Drugs and Clinical Remedies
